How to realize the precise medical treatment of depression through genetic testing?

With the increase in the number of patients with depression, the traditional "one drug for one thousand people" program can no longer meet the expectations of doctors and patients on the therapeutic effect of mental diseases, in 2020 South China Psychiatric Specialty Alliance Summit Forum on psychiatric disease pharmacogenomics lecture pointed out that through pharmacogenomics, can guide the rational use of medication, improve the safety and effectiveness of medication. Improve the safety and effectiveness of medication.

Applying pharmacogenomics research to clinical practice, Kang Li Medical can realize the goal of precise medical treatment of depression through genetic testing.

And based on the evidence-based pharmacogenomic authoritative information such as FDA drug labeling, Clinical Pharmacogenomics Implementation Consortium, Dutch Pharmacogenomics Working Group, Pharmacogenomics Knowledge Base (?P?h?a.r.m.G.K.B.?), and practice guidelines issued by various professional associations, and combining with the genetic database of the Chinese population, Cognex Medical has independently researched and developed a genetic test for the use of medication for psychiatric disorders, and has been continuously developing its genetic test for the use of medication. Based on the evidence-based pharmacogenomic information, including the Chinese population genetic database, we have independently developed a genetic test for psychiatric disorders, and have continuously optimized the algorithm and updated iteratively to provide accurate test data and guidance on medication for the clinic.